NGS versus Sanger Sequencing for Clinical Decisions
Rahul Sharma, PhD
Using NGS for sequencing that can be completed by Sanger sequencing is an unnecessary use of clinical labs' resources
Rahul Sharma, PhD
Rahul Sharma, PhD, is director of laboratory operations at Cofactor Genomics, a San Francisco-based biotech firm. He has served as head of molecular biology and technical director at the US Department of Health and Human Services, National Hansen’s Disease (Leprosy) Program. He is a science writer, consultant, and expert in molecular diagnosis, precision medicine, and CAP-CLIA, and US FDA regulations. The views, thoughts, and opinions expressed in this text belong solely to the author and are not necessarily shared by the author's employer.